Puma Biotechnology Inc (NAS:PBYI)
$ 4.84 -0.1 (-2.02%) Market Cap: 233.47 Mil Enterprise Value: 241.15 Mil PE Ratio: 15.13 PB Ratio: 4.57 GF Score: 59/100

Puma Biotechnology Inc at H C Wainwright BioConnect Conference (Virtual) Transcript

Jan 11, 2021 / 11:00AM GMT
Release Date Price: $11.51 (+1.05%)
Stephen Bersey

Hello, and welcome, everyone, to the H.C. Wainwright 2021 BioConnect Conference. My name is Stephen Bersey. I'm an equity research associate here at H.C. Wainwright. I'd like to introduce our next presenter, Alan Auerbach, who is CEO of Puma Biotechnology. They're focused on the acquisition and development of novel therapeutics for the treatment of cancer. So Alan?

Alan H. Auerbach
Puma Biotechnology, Inc. - Founder, Chairman, President, CEO & Secretary

Thank you very much, Stephen, and welcome, everyone, to the Puma Biotechnology presentation. Just a reminder, I'll be making forward-looking statements.

So on this slide, you can see all of the work that we're doing with our drug, neratinib, across the breast cancer and other cancer therapy space. The drug is currently on the market in HER2-positive breast cancer, both for the extended adjuvant indication as well as the metastatic, which is based on the Phase III results of our ExteNET trial and our NALA trial. We also have an ongoing Phase II, combining the drug with T-DM1, which is the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot